Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells
Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells
复制标题
白细胞介素2激活淋巴细胞对白血病和淋巴瘤细胞的细胞毒性
DOI：
10.1182/blood.v68.4.938.bloodjournal684938
复制
发表时间：
1986
期刊：
影响因子：
20.3
通讯作者：
H. Mizoguchi
中科院分区：
文献类型：
--
作者：
K. Oshimi;Y. Oshimi;M. Akutsu;Y. Takei;H. Saito;M. Okada;H. Mizoguchi
进行研究以确定白血病和淋巴瘤细胞是否会被自体和同种异体淋巴因子激活的杀伤（LAK）细胞溶解。将来自患者和正常供体的外周血单个核细胞（PBMC）用每mL含2，500单位重组白细胞介素2（IL-2）的培养基培养5天、2周和4周，并通过5小时51 Cr释放试验测定其细胞毒性。在从急性非淋巴细胞白血病、急性淋巴细胞白血病和非霍奇金淋巴瘤患者中分离的原发性肿瘤中，40例受试患者中有37例的肿瘤显示对正常供体LAK敏感，20例受试患者中有18例的肿瘤显示对自体LAK敏感。LAK细胞培养时间越长，细胞毒活性越低。LAK对非恶性靶细胞的细胞毒性也很低，但很显著。由于在含IL-2的培养基中扩增的PBMC主要由OKT 3阳性的泛T细胞、OKT 8阳性的抑制/细胞毒性细胞和Leu-11阳性的自然杀伤（NK）细胞组成，并且用OKT 3和Leu-11单克隆抗体（mAb）处理降低了对自体和同种异体肿瘤细胞的LAK活性，因此T细胞和NK细胞似乎都是LAK活性的效应细胞。LAK系统中的靶细胞识别机制似乎与同种异体反应性细胞毒性T淋巴细胞（CTL）中的机制不同，这是基于以下结果：虽然同种异体反应性CTL的细胞毒性通过用mAb、OKT 3和OKT 8处理效应细胞而被抑制，并且通过用与HLA I类抗原反应的mAb处理靶细胞而被抑制，但是LAK活性不被上述处理抑制。当对9例患者和2例正常人的IL-2扩增的PBMC进行染色体分析时，1例患者的PBMC显示克隆性异常染色体，5例供体的PBMC显示非克隆性异常染色体。
Studies were undertaken to determine whether leukemia and lymphoma cells would be lysed by autologous and allogeneic lymphokine-activated killer (LAK) cells. Peripheral blood mononuclear cells (PBMC) from patients and normal donors were cultured for five days, 2 weeks, and 4 weeks with medium containing 2,500 units of recombinant interleukin 2 (IL-2) per mL, and their cytotoxicity was assayed by a five-hour 51Cr- release test. Of primary tumors isolated from patients with acute nonlymphoblastic leukemia, acute lymphoblastic leukemia, and non- Hodgkin9s lymphoma, tumors of 37 out of 40 patients tested were shown to be susceptible to normal donors9 LAK, and tumors of 18 of 20 patients tested were shown to be susceptible to autologous LAK. LAK cultured for longer periods showed a tendency to have lower cytotoxicity. LAK had also low, but significant, levels of cytotoxicity for nonmalignant target cells. Because PBMC expanded in IL-2-containing medium consisted mainly of OKT3-positive pan T cells, OKT8-positive suppressor/cytotoxic cells, and Leu-11-positive natural killer (NK) cells, and treatment with OKT3 and Leu-11 monoclonal antibodies (mAb) reduced LAK activity for autologous and allogeneic tumor cells, both T and NK cells appeared to be effector cells for LAK activity. Mechanisms of target-cell recognition in the LAK system seem to be different from those in alloreactive cytotoxic T lymphocytes (CTL) based on the results that, while cytotoxicity of alloreactive CTL was inhibited by the treatment of effector cells with mAb, OKT3, and OKT8, and by the treatment of target cells with a mAb that reacts with HLA class I antigen, LAK activity was not inhibited by the above treatment. When chromosomes of IL-2-expanded PBMC in nine patients and two normal individuals were analyzed, PBMC from one patient showed chromosomes of clonal abnormalities, and PBMC from five donors showed those of nonclonal abnormalities.
DOI：
10.1073/pnas.79.14.4395
发表时间：
1982-01-01
期刊：
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES
影响因子：
--
作者：
MEUER, SC;SCHLOSSMAN, SF;REINHERZ, EL
通讯作者：
REINHERZ, EL
非T细胞急性淋巴细胞白血病的B细胞起源。
DOI：
10.1172/jci111428
发表时间：
1984
期刊：
The Journal of clinical investigation
影响因子：
--
作者：
Nadler,LM;Korsmeyer,SJ;Anderson,KC;Boyd,AW;Slaughenhoupt,B;Park,E;Jensen,J;Coral,F;Mayer,RJ;Sallan,SE
通讯作者：
Sallan,SE
DOI：
10.1073/pnas.82.24.8663
发表时间：
1985-12
影响因子：
11.1
作者：
G. H. Reem;N. Yeh;D. Urdal;P. Kilian;J. Farrar
通讯作者：
G. H. Reem;N. Yeh;D. Urdal;P. Kilian;J. Farrar